Summary

The 7 major vulvovaginal candidiasis markets reached a value of US$ 734.9 Million in 2023. Looking forward, IMARC Group expects the 7MM to reach US$ 1,058.2 Million by 2034, exhibiting a growth rate (CAGR) of 3.37% during 2024-2034.

The vulvovaginal candidiasis market has been comprehensively analyzed in IMARC's new report titled "Vulvovaginal Candidiasis Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034". Vulvovaginal candidiasis, also referred to as vaginal yeast infection, is a fungal infection that is caused by an infestation of the fungus Candida in the vulva and vagina. The most common symptoms associated with the disease are itching, burning, and soreness in the vaginal area, as well as thick, white, odorless discharge. Various other indications include pain during sex or urination, redness and swelling of the vulva, general discomfort in the genital area, etc. In some cases, women may experience recurring infections or chronic symptoms that can significantly affect their quality of life. The diagnosis of this condition typically involves a physical examination by a healthcare provider, such as a pelvic exam and a swab of the vaginal discharge for testing. The laboratory tests include a microscopic examination or culture of the discharge to determine the presence of the fungus Candida, which is the primary cause of the ailment. Several other procedures may be performed to rule out potential causes of the indications, such as sexually transmitted infections or bacterial vaginosis.

The escalating usage of antibiotics, which results in the loss of beneficial bacteria that keep the vaginal ecosystem balanced, is primarily driving the vulvovaginal candidiasis market. In addition to this, the increasing incidences of several associated risk factors, including hormonal changes, weakened immune system, sexual relations with multiple partners, poor personal hygiene, etc., are further augmenting the market growth. Moreover, the emerging popularity of over-the-counter antifungal creams containing active ingredients, such as miconazole, clotrimazole, tioconazole, etc., to treat mild to moderate symptoms of the ailment is also creating a positive outlook for the market. Apart from this, the widespread adoption of probiotics as supplements or suppositories for restoring the natural balance of bacteria in the vaginal region is acting as another significant growth-inducing factor. Additionally, the ongoing advancements of molecular diagnostic methods that can detect Candida species with high sensitivity and specificity, are further bolstering the market growth. Besides this, the rising usage of non-pharmacological therapies, such as stress-reduction techniques and dietary modifications like reducing sugar intake to manage the disease symptoms is expected to drive the vulvovaginal candidiasis market in the coming years.

IMARC Group's new report provides an exhaustive analysis of the vulvovaginal candidiasis market in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan. This includes treatment practices, in-market, and pipeline drugs, share of individual therapies, market performance across the seven major markets, market performance of key companies and their drugs, etc. The report also provides the current and future patient pool across the seven major markets. According to the report the United States has the largest patient pool for vulvovaginal candidiasis and also represents the largest market for its treatment. Furthermore, the current treatment practice/algorithm, market drivers, challenges, opportunities, reimbursement scenario and unmet medical needs, etc. have also been provided in the report. This report is a must-read for manufacturers, investors, business strategists, researchers, consultants, and all those who have any kind of stake or are planning to foray into the vulvovaginal candidiasis market in any manner.

Time Period of the Study

Base Year: 2023
Historical Period: 2018-2023
Market Forecast: 2024-2034

Countries Covered

United States
Germany
France
United Kingdom
Italy
Spain
Japan

Analysis Covered Across Each Country

Historical, current, and future epidemiology scenario
Historical, current, and future performance of the vulvovaginal candidiasis market
Historical, current, and future performance of various therapeutic categories in the market
Sales of various drugs across the vulvovaginal candidiasis market
Reimbursement scenario in the market
In-market and pipeline drugs
Competitive Landscape:
This report also provides a detailed analysis of the current vulvovaginal candidiasis marketed drugs and late-stage pipeline drugs.

In-Market Drugs

Drug Overview
Mechanism of Action
Regulatory Status
Clinical Trial Results
Drug Uptake and Market Performance

Late-Stage Pipeline Drugs

Drug Overview
Mechanism of Action
Regulatory Status
Clinical Trial Results
Drug Uptake and Market Performance

*Kindly note that the drugs in the above table only represent a partial list of marketed/pipeline drugs, and the complete list has been provided in the report.

Key Questions Answered in this Report:
Market Insights

How has the vulvovaginal candidiasis market performed so far and how will it perform in the coming years?
What are the markets shares of various therapeutic segments in 2023 and how are they expected to perform till 2034?
What was the country-wise size of the vulvovaginal candidiasis market across the seven major markets in 2023 and what will it look like in 2034?
What is the growth rate of the vulvovaginal candidiasis market across the seven major markets and what will be the expected growth over the next ten years?
What are the key unmet needs in the market?

Epidemiology Insights

What is the number of prevalent cases (2018-2034) of vulvovaginal candidiasis across the seven major markets?
What is the number of prevalent cases (2018-2034) of vulvovaginal candidiasis by age across the seven major markets?
What is the number of prevalent cases (2018-2034) of vulvovaginal candidiasis by gender across the seven major markets?
How many patients are diagnosed (2018-2034) with vulvovaginal candidiasis across the seven major markets?
What is the size of the vulvovaginal candidiasis patient pool (2018-2023) across the seven major markets?
What would be the forecasted patient pool (2024-2034) across the seven major markets?
What are the key factors driving the epidemiological trend of vulvovaginal candidiasis?
What will be the growth rate of patients across the seven major markets?

Vulvovaginal Candidiasis: Current Treatment Scenario, Marketed Drugs and Emerging Therapies

What are the current marketed drugs and what are their market performance?
What are the key pipeline drugs and how are they expected to perform in the coming years?
How safe are the current marketed drugs and what are their efficacies?
How safe are the late-stage pipeline drugs and what are their efficacies?
What are the current treatment guidelines for vulvovaginal candidiasis drugs across the seven major markets?
Who are the key companies in the market and what are their market shares?
What are the key mergers and acquisitions, licensing activities, collaborations, etc. related to the vulvovaginal candidiasis market?
What are the key regulatory events related to the vulvovaginal candidiasis market?
What is the structure of clinical trial landscape by status related to the vulvovaginal candidiasis market?
What is the structure of clinical trial landscape by phase related to the vulvovaginal candidiasis market?
What is the structure of clinical trial landscape by route of administration related to the vulvovaginal candidiasis market?

ページTOPに戻る

Table of Contents

1 Preface

2 Scope and Methodology
2.1 Objectives of the Study
2.2 Stakeholders
2.3 Data Sources
2.3.1 Primary Sources
2.3.2 Secondary Sources
2.4 Market Estimation
2.4.1 Bottom-Up Approach
2.4.2 Top-Down Approach
2.5 Forecasting Methodology

3 Executive Summary

4 Vulvovaginal Candidiasis - Introduction
4.1 Overview
4.2 Regulatory Process
4.3 Epidemiology (2018-2023) and Forecast (2024-2034)
4.4 Market Overview (2018-2023) and Forecast (2024-2034)
4.5 Competitive Intelligence

5 Vulvovaginal Candidiasis - Disease Overview
5.1 Introduction
5.2 Symptoms and Diagnosis
5.3 Pathophysiology
5.4 Causes and Risk Factors
5.5 Treatment

6 Patient Journey

7 Vulvovaginal Candidiasis - Epidemiology and Patient Population
7.1 Epidemiology - Key Insights
7.2 Epidemiology Scenario - Top 7 Markets
7.2.1 Epidemiology Scenario (2018-2023)
7.2.2 Epidemiology Forecast (2024-2034)
7.2.3 Epidemiology by Age (2018-2034)
7.2.4 Epidemiology by Gender (2018-2034)
7.2.5 Diagnosed Cases (2018-2034)
7.2.6 Patient Pool/Treated Cases (2018-2034)
7.3 Epidemiology Scenario - United States
7.3.1 Epidemiology Scenario (2018-2023)
7.3.2 Epidemiology Forecast (2024-2034)
7.3.3 Epidemiology by Age (2018-2034)
7.3.4 Epidemiology by Gender (2018-2034)
7.3.5 Diagnosed Cases (2018-2034)
7.3.6 Patient Pool/Treated Cases (2018-2034)
7.4 Epidemiology Scenario - Germany
7.4.1 Epidemiology Scenario (2018-2023)
7.4.2 Epidemiology Forecast (2024-2034)
7.4.3 Epidemiology by Age (2018-2034)
7.4.4 Epidemiology by Gender (2018-2034)
7.4.5 Diagnosed Cases (2018-2034)
7.4.6 Patient Pool/Treated Cases (2018-2034)
7.5 Epidemiology Scenario - France
7.5.1 Epidemiology Scenario (2018-2023)
7.5.2 Epidemiology Forecast (2024-2034)
7.5.3 Epidemiology by Age (2018-2034)
7.5.4 Epidemiology by Gender (2018-2034)
7.5.5 Diagnosed Cases (2018-2034)
7.5.6 Patient Pool/Treated Cases (2018-2034)
7.6 Epidemiology Scenario - United Kingdom
7.6.1 Epidemiology Scenario (2018-2023)
7.6.2 Epidemiology Forecast (2024-2034)
7.6.3 Epidemiology by Age (2018-2034)
7.6.4 Epidemiology by Gender (2018-2034)
7.6.5 Diagnosed Cases (2018-2034)
7.6.6 Patient Pool/Treated Cases (2018-2034)
7.7 Epidemiology Scenario - Italy
7.7.1 Epidemiology Scenario (2018-2023)
7.7.2 Epidemiology Forecast (2024-2034)
7.7.3 Epidemiology by Age (2018-2034)
7.7.4 Epidemiology by Gender (2018-2034)
7.7.5 Diagnosed Cases (2018-2034)
7.7.6 Patient Pool/Treated Cases (2018-2034)
7.8 Epidemiology Scenario - Spain
7.8.1 Epidemiology Scenario (2018-2023)
7.8.2 Epidemiology Forecast (2024-2034)
7.8.3 Epidemiology by Age (2018-2034)
7.8.4 Epidemiology by Gender (2018-2034)
7.8.5 Diagnosed Cases (2018-2034)
7.8.6 Patient Pool/Treated Cases (2018-2034)
7.9 Epidemiology Scenario - Japan
7.9.1 Epidemiology Scenario (2018-2023)
7.9.2 Epidemiology Forecast (2024-2034)
7.9.3 Epidemiology by Age (2018-2034)
7.9.4 Epidemiology by Gender (2018-2034)
7.9.5 Diagnosed Cases (2018-2034)
7.9.6 Patient Pool/Treated Cases (2018-2034)

8 Vulvovaginal Candidiasis - Treatment Algorithm, Guidelines, and Medical Practices
8.1 Guidelines, Management and Treatment
8.2 Treatment Algorithm

9 Vulvovaginal Candidiasis - Unmet Needs

10 Vulvovaginal Candidiasis - Key Endpoints of Treatment

11 Vulvovaginal Candidiasis - Marketed Products
11.1 List of Vulvovaginal Candidiasis Marketed Drugs Across the Top 7 Markets
11.1.1 Brexafemme (Ibrexafungerp) - SCYNEXIS
11.1.1.1 Drug Overview
11.1.1.2 Mechanism of Action
11.1.1.3 Regulatory Status
11.1.1.4 Clinical Trial Results
11.1.1.5 Sales Across Major Markets
11.1.2 Vivjoa (Oteseconazole) - Mycovia Pharmaceuticals
11.1.2.1 Drug Overview
11.1.2.2 Mechanism of Action
11.1.2.3 Regulatory Status
11.1.2.4 Clinical Trial Results
11.1.2.5 Sales Across Major Markets

Kindly note that the above only represents a partial list of marketed drugs, and the complete list has been provided in the report.

12 Vulvovaginal Candidiasis - Pipeline Drugs
12.1 List of Vulvovaginal Candidiasis Pipeline Drugs Across the Top 7 Markets
12.1.1 Prof-001 - ProFem
12.1.1.1 Drug Overview
12.1.1.2 Mechanism of Action
12.1.1.3 Clinical Trial Results
12.1.1.4 Safety and Efficacy
12.1.1.5 Regulatory Status
12.1.2 MAT2203 - Matinas BioPharma
12.1.2.1 Drug Overview
12.1.2.2 Mechanism of Action
12.1.2.3 Clinical Trial Results
12.1.2.4 Safety and Efficacy
12.1.2.5 Regulatory Status
12.1.3 Domiphen bromide/miconazole - Hyloris Pharmaceuticals/Purna Female Healthcare
12.1.3.1 Drug Overview
12.1.3.2 Mechanism of Action
12.1.3.3 Clinical Trial Results
12.1.3.4 Safety and Efficacy
12.1.3.5 Regulatory Status

Kindly note that the above only represents a partial list of pipeline drugs, and the complete list has been provided in the report.

13. Vulvovaginal Candidiasis - Attribute Analysis of Key Marketed and Pipeline Drugs

14. Vulvovaginal Candidiasis – Clinical Trial Landscape
14.1 Drugs by Status
14.2 Drugs by Phase
14.3 Drugs by Route of Administration
14.4 Key Regulatory Events

15 Vulvovaginal Candidiasis - Market Scenario
15.1 Market Scenario - Key Insights
15.2 Market Scenario - Top 7 Markets
15.2.1 Vulvovaginal Candidiasis - Market Size
15.2.1.1 Market Size (2018-2023)
15.2.1.2 Market Forecast (2024-2034)
15.2.2 Vulvovaginal Candidiasis - Market Size by Therapies
15.2.2.1 Market Size by Therapies (2018-2023)
15.2.2.2 Market Forecast by Therapies (2024-2034)
15.3 Market Scenario - United States
15.3.1 Vulvovaginal Candidiasis - Market Size
15.3.1.1 Market Size (2018-2023)
15.3.1.2 Market Forecast (2024-2034)
15.3.2 Vulvovaginal Candidiasis - Market Size by Therapies
15.3.2.1 Market Size by Therapies (2018-2023)
15.3.2.2 Market Forecast by Therapies (2024-2034)
15.3.3 Vulvovaginal Candidiasis - Access and Reimbursement Overview
15.4 Market Scenario - Germany
15.4.1 Vulvovaginal Candidiasis - Market Size
15.4.1.1 Market Size (2018-2023)
15.4.1.2 Market Forecast (2024-2034)
15.4.2 Vulvovaginal Candidiasis - Market Size by Therapies
15.4.2.1 Market Size by Therapies (2018-2023)
15.4.2.2 Market Forecast by Therapies (2024-2034)
15.4.3 Vulvovaginal Candidiasis - Access and Reimbursement Overview
15.5 Market Scenario - France
15.5.1 Vulvovaginal Candidiasis - Market Size
15.5.1.1 Market Size (2018-2023)
15.5.1.2 Market Forecast (2024-2034)
15.5.2 Vulvovaginal Candidiasis - Market Size by Therapies
15.5.2.1 Market Size by Therapies (2018-2023)
15.5.2.2 Market Forecast by Therapies (2024-2034)
15.5.3 Vulvovaginal Candidiasis - Access and Reimbursement Overview
15.6 Market Scenario - United Kingdom
15.6.1 Vulvovaginal Candidiasis - Market Size
15.6.1.1 Market Size (2018-2023)
15.6.1.2 Market Forecast (2024-2034)
15.6.2 Vulvovaginal Candidiasis - Market Size by Therapies
15.6.2.1 Market Size by Therapies (2018-2023)
15.6.2.2 Market Forecast by Therapies (2024-2034)
15.6.3 Vulvovaginal Candidiasis - Access and Reimbursement Overview
15.7 Market Scenario - Italy
15.7.1 Vulvovaginal Candidiasis - Market Size
15.7.1.1 Market Size (2018-2023)
15.7.1.2 Market Forecast (2024-2034)
15.7.2 Vulvovaginal Candidiasis - Market Size by Therapies
15.7.2.1 Market Size by Therapies (2018-2023)
15.7.2.2 Market Forecast by Therapies (2024-2034)
15.7.3 Vulvovaginal Candidiasis - Access and Reimbursement Overview
15.8 Market Scenario - Spain
15.8.1 Vulvovaginal Candidiasis - Market Size
15.8.1.1 Market Size (2018-2023)
15.8.1.2 Market Forecast (2024-2034)
15.8.2 Vulvovaginal Candidiasis - Market Size by Therapies
15.8.2.1 Market Size by Therapies (2018-2023)
15.8.2.2 Market Forecast by Therapies (2024-2034)
15.8.3 Vulvovaginal Candidiasis - Access and Reimbursement Overview
15.9 Market Scenario - Japan
15.9.1 Vulvovaginal Candidiasis - Market Size
15.9.1.1 Market Size (2018-2023)
15.9.1.2 Market Forecast (2024-2034)
15.9.2 Vulvovaginal Candidiasis - Market Size by Therapies
15.9.2.1 Market Size by Therapies (2018-2023)
15.9.2.2 Market Forecast by Therapies (2024-2034)
15.9.3 Vulvovaginal Candidiasis - Access and Reimbursement Overview

16 Vulvovaginal Candidiasis - Recent Events and Inputs From Key Opinion Leaders

17 Vulvovaginal Candidiasis Market - SWOT Analysis
17.1 Strengths
17.2 Weaknesses
17.3 Opportunities
17.4 Threats

18 Vulvovaginal Candidiasis Market – Strategic Recommendations

19 Appendix